Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMM 6 415

Next Previous
Drug Profile

IMM 6 415

Alternative Names: IMM-6-415

Latest Information Update: 11 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immuneering
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 11 Jun 2025 Immuneering Corporation completes a phase I/II trial in Solid tumours (Inoperable/unresectable, Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA (PO) (NCT06208124)
  • 27 Feb 2024 Phase-I/II clinical trials in Solid tumours (Inoperable/unresectable, Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA (PO) (NCT06208124)
  • 12 Dec 2023 Immuneering plans a phase I/IIa trial for Solid tumours (Late-stage disease) in early 2024 (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top